Teva’s New Copaxone Gaining Market Share Ahead Of Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.
You may also be interested in...
Emerging Markets Earnings: Teva Moves On With Russia, LatAm In Focus
Teva appears to have eased past a management shakeup and extended its lead in Copaxone with the company ready to expand in emerging markets as the next frontier, led by Russia and Latin America.
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.